-
Mashup Score: 5
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 114
Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), particularly among KRAS-mutant cases. However, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1del 13.7% SMARCA4del -assoc w ⬇️PD-L1, TMB -assoc w ⬇️ORR, PFS, OS from chemoIO in DFCI & MSKCC cohorts @OncoAlert @JTOonline #LCSM https://t.co/PxXwc6VH0r
-
-
Mashup Score: 114
Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), particularly among KRAS-mutant cases. However, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1del 13.7% SMARCA4del -assoc w ⬇️PD-L1, TMB -assoc w ⬇️ORR, PFS, OS from chemoIO in DFCI & MSKCC cohorts @OncoAlert @JTOonline #LCSM https://t.co/PxXwc6VH0r
-
-
Mashup Score: 16
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival.
Source: www.ilcn.orgCategories: General Medicine News, Oncologists1Tweet-
Discover why experts recommend smoking cessation as a first-line intervention for lung cancer. Explore the latest data in ILCN: https://t.co/0gOW6hXjTw #LCSM
-
-
Mashup Score: 111
Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC), particularly among KRAS-mutant cases. However, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1del 13.7% SMARCA4del -assoc w ⬇️PD-L1, TMB -assoc w ⬇️ORR, PFS, OS from chemoIO in DFCI & MSKCC cohorts @OncoAlert @JTOonline #LCSM https://t.co/PxXwc6VH0r
-
-
Mashup Score: 5Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC - ILCN.org (ILCN/WCLC) - 5 day(s) ago
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Catch up on the latest insights and key takeaways from the final plenary session of the 2024 ACLC in Hong Kong. Visit ILCN for more: https://t.co/cyzeMFaBcV #LCSM
-
-
Mashup Score: 0
A phase 1a/1b trial showed that ZL-1310 elicited an ORR of 74%, all of which were PRs, in patients with SCLC who received prior chemotherapy.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
At a median follow-up of 2.4 months (range, 0.3-6.5), the ORR, including patients with unconfirmed responses, was 74% (95% CI, 48.8%-90.9%). #lcsm https://t.co/EO4yavky9F
-
-
Mashup Score: 2Kim Evaluates New Regimens for EGFR+ Lung Cancer - 8 day(s) ago
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR+ lung cancer. #lcsm | @DrEdKim @cityofhope @cityofhopeoc https://t.co/MO0rXaDc3y https://t.co/dYgDQG3mEJ
-
-
Mashup Score: 5
In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Roundtable Roundup: Lung Cancer Molecular Testing and ALK-Targeted Treatment | #lcsm @vincentlamMD @hopkinskimmel @chulkimMD https://t.co/Tkh2czKAHi https://t.co/QzUaWhFxL8
-
-
Mashup Score: 1
Interim analysis data show improvements in overall survival with OST-HER2 in this osteosarcoma population compared with historical controls.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
At 12 months, the EFS rate was 33% with OST-HER2 in the phase 2b trial compared with 20% in a peer-reviewed historical control cohort. #lcsm https://t.co/hheMqqbug2
-
Is there a new standard of care for EGFR-mutated lung cancer? Read the latest findings from the MARIPOSA trial in ILCN: https://t.co/YfntqKSYZC #LCSM